UBS raised the firm’s price target on Cencora (COR) to $335 from $298 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Strategic Growth and Industry Positioning Justify Buy Rating
- Cencora price target raised to $288 from $263 at Morgan Stanley
- Cardinal Health price target raised to $155 from $150 at BofA
- Cencora price target raised to $285 from $270 at BofA
- McKesson price target raised to $755 from $665 at BofA